Minerva Urologica E Nefrologica最新文献

{"title":"Robot-assisted laparoscopic pyeloplasty in children: a systematic review.","authors":"Lorenzo Masieri,&nbsp;Simone Sforza,&nbsp;Antonio A Grosso,&nbsp;Francesca Valastro,&nbsp;Riccardo Tellini,&nbsp;Chiara Cini,&nbsp;Luca Landi,&nbsp;Maria Taverna,&nbsp;Antonio Elia,&nbsp;Alberto Mantovani,&nbsp;Andrea Minervini,&nbsp;Marco Carini","doi":"10.23736/S0393-2249.20.03854-0","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.03854-0","url":null,"abstract":"<p><strong>Introduction: </strong>Open pyeloplasty has been the first-line treatment for uretero-pelvic junction obstruction for decades. In the last years, minimally-invasive surgery (MIS) has gained popularity in the pediatrics field. Furthermore, recently, a great extension of Robot-assisted laparoscopic pyeloplasty (RALP) has been seen in younger and lighter-weight children as well as in redo cases. Herein we provided a comprehensive review of primary and redo RALP performed in children, particularly focusing on the different distribution of outcomes among the ages.</p><p><strong>Evidence acquisition: </strong>A systematic review of the literature was performed according to PRISMA recommendations and was conducted on surgical indication and technique, intraoperative nuances, peri- and postoperative outcomes of primary and redo RALP.</p><p><strong>Evidence synthesis: </strong>Overall, 33 studies with 1448 patients were included for primary RALP and 7 studies with 101 patients for redo cases between 2000 and 2019. In particular, 4 studies aimed to compare RALP in different cohorts of children grouped on ages or weight and 4 studies evaluated technical feasibility and safety of RALP over laparoscopic and open approach in very young populations. Success rate for primary RALP was found >90% in all studies but one, with low complication rate and preoperative indication. In redo series, 96% of patients revealed a decreased hydronephrosis on postoperative imaging.</p><p><strong>Conclusions: </strong>RALP offers excellent outcomes in the pediatric population. However, there is still a strong need for higher quality evidence in the form of prospective observational studies and clinical trials. The rising of new robotic systems, such as single-port platform, might further enhance the applications of RALP in children.</p>","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":" ","pages":"673-690"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38233476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The invisible impact of COVID-19: indirect mortality in urology.","authors":"J. V. Sánchez-González*, O. Colet, F. Gómez-Palomo, J. Pérez-Ardavín, A. Bernal, F. Boronat","doi":"10.23736/S0393-2249.20.04119-3","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.04119-3","url":null,"abstract":"","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73292776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.","authors":"Consuelo Buttigliero,&nbsp;Marcello Tucci,&nbsp;Cristina Sonetto,&nbsp;Francesca Vignani,&nbsp;Rosario F Di Stefano,&nbsp;Chiara Pisano,&nbsp;Fabio Turco,&nbsp;Gaetano Lacidogna,&nbsp;Pamela Guglielmini,&nbsp;Gianmauro Numico,&nbsp;Giorgio V Scagliotti,&nbsp;Massimo Di Maio","doi":"10.23736/S0393-2249.20.03708-X","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.03708-X","url":null,"abstract":"<p><strong>Background: </strong>Previous studies demonstrated a predictive value of prostate-specific antigen (PSA) kinetics for treatment outcome. Our retrospective study evaluates the prognostic role of early PSA drop in metastatic castration resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA) or enzalutamide (E).</p><p><strong>Methods: </strong>All mCRPC patients treated with AA or E at the San Luigi Hospital in Orbassano between 2010 and 2018 and at the Ordine Mauriziano Hospital in Turin between 2014 and 2018 were included in this retrospective study. Only patients with an early PSA (measured 28-60 days after the beginning of the treatment) were included in the analysis. Patients were divided in early responders and non-early responders according to early PSA response (drop≥50% from baseline). Univariate and multivariate analyses for progression free survival (PFS) and overall survival (OS) were performed.</p><p><strong>Results: </strong>Of 144 patients with early PSA value, 61 (42.4%) patients received E (docetaxel-naïve 42, post-docetaxel 19) and 83 (57.6%) received AA (docetaxel-naïve 44, post-docetaxel 39). Seventy-five (52.1%) patients achieved early PSA drop. In docetaxel-naïve setting (N.=86), median PFS was 14.9 (with early PSA drop) vs. 8.8 months (without early PSA drop, P=0.001). In post-docetaxel setting (N.=58) median PFS was 11.9 vs. 4.5 months (P<0.001). Globally, median PFS was 14.9 vs. 6.3 months in patients with and without early PSA drop, respectively (P<0.001). In docetaxel-naïve setting, patients with early PSA drop had a median OS of 39.5 vs. 18.8 months (P=0.12). In post-docetaxel setting median OS was 29.6 vs. 10.7 months (P=0.01). Comprehensively, median OS was 31.9 vs. 16.3 (P=0.002) in patients with and without early PSA drop, respectively. At multivariate analysis, early PSA drop confirmed an independent association with PFS (HR 0.21; 95% CI: 0.12-0.38, P<0.001) and OS (HR 0.25; 95% CI: 0.12-0.50, P<0.001).</p><p><strong>Conclusions: </strong>mCRPC patients treated with AA or E, in docetaxel-naïve or post-docetaxel setting, with early PSA drop had significantly better OS and PFS.</p>","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":" ","pages":"737-745"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37830107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous tumor ablation versus partial nephrectomy for small renal mass: the impact of histologic variant and tumor size.","authors":"L. Bianchi, F. Mineo Bianchi, F. Chessa, U. Barbaresi, C. Casablanca, P. Piazza, A. Mottaran, M. Droghetti, C. Roveroni, E. Balestrazzi, G. Gentile, C. Gaudiano, A. Bertaccini, E. Marcelli, A. Porreca, B. de Concilio, C. Serra, A. Celia, E. Brunocilla, R. Schiavina","doi":"10.23736/S0393-2249.20.03983-1","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.03983-1","url":null,"abstract":"BACKGROUND\u0000To investigate recurrence rates in patients with T1 renal cell carcinoma (RCC) undergone partial nephrectomy (PN), radiofrequency ablation (RFA) or cryoablation (Cryo).\u0000\u0000\u0000METHODS\u0000We retrospectively evaluated data from 665 (81.4%), 68 (8.3%) and 83 (10.3%) patients who underwent PN, RFA and Cryo, respectively. Kaplan-Meier curves depict recurrence-free survival (RFS) rates in the overall population and after stratifying according to tumor's histology (namely, clear cell RCC and non-clear RCC) and size (namely < 2 cm and 2-4 cm). Multivariable Cox regression model was used to identify predictors of recurrence. Cumulative-incidence plots evaluated disease recurrence and other causes of mortality (OCM).\u0000\u0000\u0000RESULTS\u0000Patients referred to PN experienced higher RFS rate compared to those treated with RFA and Cryo at 60-month in the overall population (96.4% vs. 79.4 % vs. 87.8%), in patients with clear cell RCC (93.3% vs 75% vs. 80.4%) and in those with tumor of 2-4 cm (97.3% vs 78% and 84.4%; all p≤0.01). In patients with non-clear cell RCC and with tumor <2cm, PN showed higher RFS rate at 60-month as compared to RFA (97.9% vs 84.4% and 95.1% vs 78.1%, respectively; all p≤0.02). At multi-variate analysis, ablative techniques (RFA [HR=4.03] and Cryo [HR=3.86]) were independent predictors of recurrence (all p<0.03). At competing risks analysis, recurrence rate and OCM were 7.3% and 1.3% vs 25% and 7.2% vs 19.9% and 19.9% for PN, RFA and Cryo, respectively.\u0000\u0000\u0000CONCLUSIONS\u0000PN and Cryo showed similar RFS rates in patients with non-clear cell RCC and with renal mass < 2cm.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88481209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of anticoagulant and antiplatelet drugs therapy on perioperative outcomes of purely off-clamp robot-assisted partial nephrectomy: a single-center experience.","authors":"U. Anceschi, A. Brassetti, Giulia Torregiani, G. Tuderti, M. Costantini, R. Mastroianni, A. Bove, M. Ferriero, M. Gallucci, G. Simone","doi":"10.23736/S0393-2249.20.04179-X","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.04179-X","url":null,"abstract":"correlates with a better functional outcome: lower drop in estimated renal plasma flow (ERPF) at renal scan at three months of follow-up (-12.38 in 3D group vs. -18.14 in US group; p[0.01). CONCLUSIONS: The use of HA3DTM models during RAPN for complex tumours can be useful for identifying the lesion and intraparenchymal structures that are difficult to visualize with US only. This translates to a potential improvement in the quality of the resection phase and a better functional recovery.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76106811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors for opioid-free management after robotic radical prostatectomy: the value of the SP® Robotic Platform.","authors":"G. Sawczyn, L. Lenfant, A. Aminsharifi, S. Kim, J. Kaouk","doi":"10.23736/S0393-2249.20.04038-2","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.04038-2","url":null,"abstract":"BACKGROUND\u0000The objective was to evaluate perioperative factors associated with opioid-free management after robotic radical prostatectomy in a single institution.\u0000\u0000\u0000METHODS\u0000From January 2019 to January 2020, data from patients who underwent robotic radical prostatectomy was retrospectively entered in a pre-approved IRB database. Data were analyzed according to the postoperative opioid administration in hospital and/or after discharge. Robotic radical prostatectomy was performed using either the standard multi-port Da Vinci Si robotic platform with a transperitoneal approach(MP-RALP) or the novel DaVinci SP® robotic platform with an extraperitoneal approach(SP-EPP). Patients undergoing minimally invasive surgery were included in the \"enhanced recovery after surgery\"(ERAS) protocol regardless of the surgery approach.\u0000\u0000\u0000RESULTS\u0000During the study period, 210 patients matched the selection criteria. Of those, 158(75%) patients received opioids during the hospital stay or after discharge and 52(25%) patients never received opioids. SP-EPP surgical approach and shorter LOS were predictors of never receiving opioids (Odds Ratio [OR]=4.97, (95% CI 1.81-14.77, p=0.002 and OR=0.56, CI 95% 0.35-0.86, p=0.011, respectively). SP-EPP surgical approach was increasing the odds of remaining opioid free whether in-hospital or after discharge (OR= 11.97, 95% CI 4.8 - 32, p<0.0001 and OR=11.6, 95% CI 4.6-31, p<0.0001, respectively). Finally, a high BMI increased the odds of receiving opioid in hospital or after discharge (OR=0.89, 95% CI 0.82-0.96, p=0.003 and OR=0.89, 95% CI 0.82-0.96, p=0.002, respectively).\u0000\u0000\u0000CONCLUSIONS\u0000In this series, after robotic radical prostatectomy the use of a less invasive approach (SP-EPP), a shorter LOS and a lower BMI, were predictive of opioid-free status.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85695521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smart learning for urology residents during the COVID-19 pandemic and beyond: insights from a nationwide survey in Italy.","authors":"Francesco Claps,&nbsp;Daniele Amparore,&nbsp;Francesco Esperto,&nbsp;Giovanni Cacciamani,&nbsp;Cristian Fiori,&nbsp;Andrea Minervini,&nbsp;Giovanni Liguori,&nbsp;Carlo Trombetta,&nbsp;Francesco Porpiglia,&nbsp;Sergio Serni,&nbsp;Enrico Checcucci,&nbsp;Riccardo Campi","doi":"10.23736/S0393-2249.20.03921-1","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.03921-1","url":null,"abstract":"","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":" ","pages":"647-649"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37955492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En-bloc resection of bladder tumors for pathological staging: the value of lateral margins analysis.","authors":"Ahmed Eissa,&nbsp;Ahmed Zoeir,&nbsp;Silvia Ciarlariello,&nbsp;Luca Sarchi,&nbsp;Maria C Sighinolfi,&nbsp;Ahmed Ghaith,&nbsp;Stefano Puliatti,&nbsp;Raffaele Inzillo,&nbsp;Luca Reggiani Bonetti,&nbsp;Mino Rizzo,&nbsp;Bernardo Rocco,&nbsp;Salvatore Micali","doi":"10.23736/S0393-2249.20.03551-1","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.03551-1","url":null,"abstract":"<p><strong>Background: </strong>In endoscopic resection of colorectal tumors, the pathological assessment of the lateral margins is a strong predictor of tumor recurrence after resection. The aim of the current study is to evaluate the value of the peritumoral margins assessment in ERBT on tumor recurrence.</p><p><strong>Methods: </strong>We retrospectively analyzed the data of 50 consecutive patients with NMIBC and treated by ERBT between January and December 2017.</p><p><strong>Results: </strong>The lateral margins showed dysplasia in 16 patients and malignancy in three patients. Local recurrence occurred in 14 (28%) patients. It was noted that 57% of patients with recurrence showed some degree of dysplasia or malignancy in the lateral margin; however, on multivariate logistic regression lateral margins lesions were not significantly associated with recurrence (OR 2.175, 95% CI: 0.430-10.996, P=0.35).</p><p><strong>Conclusions: </strong>ERBT may improve the pathological report of bladder tumor. There was a trend toward increased rate of recurrence in patients with dysplasia or malignancy in their lateral margins; however, this was not statistically significant on multivariate analysis. Further studies with larger sample sizes are required to assess the value of lateral margin analysis.</p>","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":" ","pages":"763-769"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37597569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trimodal therapy in muscle invasive bladder cancer management.","authors":"Elvira Polo-Alonso,&nbsp;Cynthia Kuk,&nbsp;Georgi Guruli,&nbsp;Asit K Paul,&nbsp;George Thalmann,&nbsp;Ashish Kamat,&nbsp;Eduardo Solsona,&nbsp;George Thalmann,&nbsp;Alfredo I Urdaneta,&nbsp;Alexandre R Zlotta,&nbsp;Maria C Mir","doi":"10.23736/S0393-2249.20.04018-7","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.04018-7","url":null,"abstract":"<p><strong>Introduction: </strong>Radical cystectomy (RC) is the current mainstay for muscle-invasive bladder cancer (MIBC). Concerns regarding morbidity, mortality and quality of life have favored the introduction of bladder sparing strategies. Trimodal therapy, combining transurethral resection, chemotherapy and radiotherapy is the current standard of care for bladder preservation strategies in selected patients with MIBC.</p><p><strong>Evidence acquisition: </strong>A comprehensive search of the Medline and Embase databases was performed. A total of 19 studies were included in a systematic review of bladder sparing strategies in MIBC management was carried out following the preferred reporting items for systematic reviews and meta-analysis (PRISMA).</p><p><strong>Evidence synthesis: </strong>The overall median complete response rate after trimodal therapy (TMT) was 77% (55-93). Salvage cystectomy rate with TMT was 17% on average (8-30). For TMT, the 5-year cancer-specific survival and overall survival rates range from 42-82% and 32-74%, respectively. Currently data supporting neoadjuvant or adjuvant chemotherapy in bladder sparing approaches are emerging, but robust definitive conclusions are still lacking. Gastrointestinal toxicity rates are low around 4% (0.5-16), whereas genitourinary toxicity rates reached 8% (1-24). Quality of life outcomes are still underreported.</p><p><strong>Conclusions: </strong>Published data and clinical experience strongly support trimodal therapy as an acceptable bladder sparing strategy in terms of oncological outcomes and quality of life in selected patients with MIBC. A strong need exists for specialized centers, to increase awareness among urologists, to discuss these options with patients and to stress the increased participation of patients and their families in treatment path decision-making.</p>","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":" ","pages":"650-662"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38326458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis.","authors":"Chengquan Ma, I. R. Abeysekera, Wen-Jing Xu, Ying Wang, Jianjun Peng, Hongjun Li","doi":"10.23736/S0393-2249.20.03756-X","DOIUrl":"https://doi.org/10.23736/S0393-2249.20.03756-X","url":null,"abstract":"INTRODUCTION\u0000To compare the risk of cardiovascular disease (CVD) following gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist therapy for patient with prostate cancer (PCa).\u0000\u0000\u0000EVIDENCE ACQUISITION\u0000We searched PubMed, Web of science, Opengery, Cochrane library databases and international congress reports for studies published before December 2019. This meta-analysis was conducted using Stata version 12.0. Relative ratios (RRs) and their credible intervals (CI) were applied for the cardiovascular safety evaluation of androgen-deprivation therapy (ADT) medical interventions, including GnRH agonist and GnRH antagonist therapy. In addition, fixed-effect or random-effect models were applied in the statistical analyses according to the heterogeneity.\u0000\u0000\u0000EVIDENCE SYNTHESIS\u0000Six articles including 32,997 participants were analyzed with a random effects model. The results of meta-analysis showed that compared with GnRH agonist, the incidents of CVD was equal to GnRH antagonist therapy for patient with PCa (RR 0.98, 95% CI 0.94-1.02). When considering, under sub-group analysis with randomized controlled trials (RCTs) or controlled clinical trials (CCTs), no statistical differences in risk of CVD were found in two sub-group analyses. No evidence of publication bias was found in our meta-analysis by a funnel plot (Pr> | z |=0.26).\u0000\u0000\u0000CONCLUSIONS\u0000This meta-analysis indicates that compared treatment with GnRH antagonist, risks of CVD in PCa patients was the same as GnRH agonist. Further RCTs are strongly required to provide more definitive evidence.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75454867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}